Slides
Page 1
Corporate PresentationOctober 2026 © 2026 Vera Therapeutics, Inc. Corporate Presentation
Page 2
2© 2026 Vera Therapeutics, Inc. Corporate Presentation Forward-looking statementsDisclaimerThis material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements in this presentation that are not statements of historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, TRUTAKNA™'s ability to transform treatment of autoimmune disease; the expected timing of sBLA submission for TRUTAKNA; the potential for TRUTAKNA to offer precision modulation of B cells and autoantibodies;the timing of and potential for the U.S. FDA to grant full approval of TRUTAKNA; the ability for TRUTAKNA to achieve results that reflect comprehensive disease modification in IgAN;the estimated IgAN epidemiology in 2032; the potential for TRUTAKNA to achieve the KDIGO Clinical Practice Guidelines; the potential market opportunity in pipeline autoimmune diseases; the commercial opportunity of IgAN and TRUTAKNA; and the Company's expectations regarding the timing of clinical trial results for EXTEND and PIONEER trials.Words such as “anticipate,” “plan,” “expect,” “will,” “may,” “potential,” “projected,” “promise” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks related to the regulatory approval process, the potential that results of earlier clinical trials may not be obtained in later clinical trials, risks and uncertainties associated with the Company's business in general, the impact of macroeconomic and geopolitical events, and the other risks described in the Company's filings with the U.S. Securities and Exchange Commission, including those described under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation, and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. This presentation discusses product candidates that are under clinical study and which have not yet been fully approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied to the extent it has not yet been approved. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.
Page 3
3© 2026 Vera Therapeutics, Inc. Corporate Presentation DisclaimerIndication: TRUTAKNA™ (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.Important Safety InformationContraindications: TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients of TRUTAKNA.Warnings and PrecautionsImmunosuppression and Increased Risk of Infections: TRUTAKNA suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic infection or recurring infections may have an increased risk of serious infection. In clinical trials, infections were reported in 32% of TRUTAKNA patients compared with 28% of placebo patients.Before initiating TRUTAKNA, assess patients for active infections. Delay TRUTAKNA administration in patients with active infection until the infection resolves or is adequately treated. Monitor patients for signs and symptoms of infection during treatment with TRUTAKNA. If a serious infection develops, consider interrupting TRUTAKNA until the infection is controlled.The concomitant use of TRUTAKNA and other immune-modulating therapies has not been evaluated. Concomitant use of TRUTAKNA with drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.Immunosuppression and Immunization Risk: TRUTAKNA may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Prior to initiating treatment with TRUTAKNA, complete all age-appropriate immunizations. Live vaccines are not recommended within 30 days prior to initiation or during treatment with TRUTAKNA as safety of coadministration has not been established.Adverse Reactions: The most common adverse reactions (≥5%) in patients treated with TRUTAKNA and placebo, respectively, were infections (32% vs 28%) and local administration reactions (30% vs 5%). The most common infection was upper respiratory tract infection (12% vs 9%), and the most common local administration reactions were injection site reaction (19% vs 2%) and injection site erythema (6% vs 1%).Use in Specific PopulationsPregnancy: Available data on TRUTAKNA used in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.Based on the mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant. Consider the potential clinical impact of TRUTAKNA exposure in infants exposed in utero. Pregnant women exposed to TRUTAKNA, or their healthcare provider, should report TRUTAKNA exposure by calling 1-833-633-8372.Pediatric Use: The safety and effectiveness of TRUTAKNA in pediatric patients have not been established.You may report side effects to the FDA at 1-800-FDA-1088 orwww.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA ormedinfo@veratx.com.Please see fullPrescribing Informationfor additional Important Safety Information.This presentation includes data not in the FDA-approved Prescribing Information for TRUTAKNA and discusses investigational uses of TRUTAKNA that are not approved. No representation is made as to the safety or effectiveness of TRUTAKNA for the uses under investigation.
Page 4
4© 2026 Vera Therapeutics, Inc. Corporate Presentation •VERA (Nasdaq) is a San Francisco-based biotechnology company with world-class development and commercialization leadership•First commercial product: TRUTAKNA™ (atacicept-vymj),a first-in-class BAFF and APRIL inhibitor that could transform treatment of autoimmune disease•FDA granted accelerated approval in IgAN•Phase 3 final efficacy analysis presented at ASN Kidney Week 2026 opening plenary session, simultaneously published in The New England Journal of Medicine•Planned sBLA submission in Q4 2026 for potential full approval in 2027APRIL, A proliferation-inducing ligand; BAFF, B-cell activating factor, also known as B lymphocyte stimulator (BLyS); IgAN, immunoglobulin A nephropathy; sBLA, supplemental Biologics License Application.
Page 5
5© 2026 Vera Therapeutics, Inc. Corporate Presentation Vera pipelineResearch & DiscoveryPreclinicalClinicalMarketed TRUTAKNA IgAN pMN, FSGS, MCDPotential future autoimmune indicationsMAU868BK virus VT-109Potential future autoimmune indicationsVera holds worldwide, exclusive rights to develop and commercialize TRUTAKNA, VT-109, and MAU868 Phase 2 Phase 2 FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; pMN, primary membranous nephropathy.
Page 6
6© 2026 Vera Therapeutics, Inc. Corporate Presentation Management team: Successful clinical and commercial track record Marshall Fordyce, MDFounder and CEO Lauren Frenz, MBAChief Business Officer Sean Grant, MBA Chief Financial Officer Robert Brenner, MDChief Medical Officer David Johnson, MBAChief Operating Officer Matt SkeltonChief Commercial Officer Jane Wright-MitchellChief Legal Officer Nancy Boman, MD, PhDChief Regulatory Officer
Page 7
7© 2026 Vera Therapeutics, Inc. Corporate Presentation ~$499MCash, cash equivalents, and marketable securities(as of 6.30.26) ~72.1MShares outstanding(as of 7.29.26) Strong financial position Additional $425M non-dilutive capital available through Oxford Facility,subject to satisfaction of certain conditions
Page 8
8© 2026 Vera Therapeutics, Inc. Corporate Presentation Inhibition of immune complex formation in IgAN may offer the potential to avoidend-stage kidney disease during a patient’s lifetime ESKD, end stage kidney disease.1. US CDC Cancer Statistics based on cancers diagnosed from 2015 to 2021 and follow-up of patients through Dec 31, 2021; 2. Thurlow JS, et al. Am J Nephrol 2021 (data for ESKD resulting from all kidney disease). ESKD 5-year mortalitycomparable to cancer 7159 35 80 20 40 60 80 LungCancerESKDColorectalCancerBreastCancer 5-Year % Mortality in US1,2
Page 9
9© 2026 Vera Therapeutics, Inc. Corporate Presentation Atacicept: Rationally designed fusion protein conceived in the era of modern biotechnology CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; Fc, fragment crystallizable region; Gd-IgA1, galactose-deficient immunoglobulin A1; TACI, transmembrane activator and calcium-modulator and cyclophilin ligand interactor.1. KDIGO IgAN and IgAV Work Group. Kidney Int. 2025;108(4S):S1-S71. 2. Barratt J, et al. N Engl J Med 2026 doi/full/10.1056/NEJMoa2610103. These data are from multiple trials and not a head-to-head clinical trial; such data may not be directly comparable due to differences in composite kidney outcome definitions, study protocols, conditions and patient populations. APRIL TACIBAFF B cell TACI receptordomainsFc domainof IgG1 Atacicept•Rationally designed native human TACI-Fc fusion protein•Soluble receptor binds key cytokines, BAFF and APRIL, with picomolar binding affinity•Designed for precision modulation of B cells mL/min/year (physiological rate)1<1~16–55%Treatment goal: reduce rate of eGFR loss toLandmark trials of CKD therapies reportedrisk reductions in composite kidney disease outcomes2 Gd-IgA1reduction ProteinuriareductionHematuriaresolutioneGFR stabilization,kidney protection IgAN is a disease of B cell origin with kidney pathology
Page 10
10© 2026 Vera Therapeutics, Inc. Corporate Presentation ORIGIN Phase 2b long-term results appear consistent with disease modification Stabilization of eGFR Resolution of hematuria Reduction in proteinuria Reduction in Gd-IgA1 -1 0 -5 0 5 10 01224364860728496 -1 00-8 0-6 0-4 0-2 00 01224364860728496-7 5-6 0-4 5-3 0-1 50 Mean ± SE Change from Baseline in eGFR, mL/min/1.73m2 Mean ± SE % Change from Baseline in Gd-IgA1 -0.6 -66% -6 0 -4 0 -2 0 0 01224364860728496 Mean ± SE % Change from Baseline in UPCR -52% Change from Baselinein % Participants (95% CI)-75% Slope Week from First Atacicept Dose Week from First Atacicept Dose Mean eGFR change from baselineAnnualized eGFR slope of -0.6 mL/min/1.73m2 per year Week from First Atacicept Dose Week from First Atacicept Dose mL/min/year 967260483624120 Data includes all participants receiving any active dose at any time point, with baseline (BL, week 0) defined as last available measurement prior to first active dose. Results through 96 weeks were exploratory endpoints and included open-label treatment. CI, confidence interval; UPCR, urine protein creatinine ratio.Barratt J, et al. J Am Soc Nephrol2025.
Page 11
11© 2026 Vera Therapeutics, Inc. Corporate Presentation ORIGIN 3 trial design Endpoints•Primary: UPCR-24h % change from baseline at 36 weeks•Secondary endpoints tested in a prespecified, fixed-sequence hierarchy:–Key: eGFR change from baseline at 52 weeks–Annualized eGFR slope through 104 weeks–UPCR-24h % change from baseline at 52 weeks–Gd-IgA1 % change from baseline at 52 weeks–Hematuria resolution at 52 weeks–Time to first sustained ≥30% eGFR decline through 104 weeks–Time to first composite kidney-disease progression event through 104 weeks•Safety Key Inclusion Criteria•Patients ≥18 years old with biopsy-proven IgAN and high risk of disease progression•UPCR-24h ≥1.0 g/g or UP ≥1.0 g/24h•eGFR ≥30 mL/min/1.73m2•Stable and optimized RASi for ≥12 weeks, use of SGLT2i allowed•Blood pressure ≤150/90 mmHgKey Exclusion Criteria•IgAN secondary to another condition•Nephrotic syndrome within 6 months of screening•Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 3 months of screening Double-blind treatment*Open-label extension Week0TRUTAKNA 150 mg SC QWPlacebo TRUTAKNA 150 mg SC QW 1563652 104 Multinational, randomized, placebo-controlled trial of TRUTAKNA, self-administered at home via weekly 1-mL SC injection 1° Endpoint metFinal analysis: 2° Endpoints met
Page 12
12© 2026 Vera Therapeutics, Inc. Corporate Presentation Primary endpoint: UPCR reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received ≥1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed using a mixed-effects model with repeated measurement (MMRM). Mean (95% CI) % Change from Baseline n=PlaceboTRUTAKNA -60-50-40-30-20-10010 0 12 24 36Week97106 96104 97104 95103 Δ 42%95% CI 29, 52p<0.0001 -60-50-40-30-20-10010 -46%95% CI -53, -38 -7%95% CI -19, 8 Placebon=95TRUTAKNAn=103
Page 13
13© 2026 Vera Therapeutics, Inc. Corporate Presentation TRUTAKNA was generally well tolerated in ORIGIN 3 interim analysis •Most adverse events were mild or moderate in severity and resolved without treatment interruption or discontinuation•Rate of serious adverse events was lower in the atacicept group compared with placebo •No clinically relevant hypogammaglobulinemia •No clinically significant effect of anti-drug antibodies on PK, PD, safety or efficacy•No deaths occurred Participants, %TRUTAKNAn=214Placebon=214Most common adverse events (≥5%)Infections3228Upper respiratory tract infection129Local administration reactions305Injection site reaction192Injection site erythema61Serious adverse events1 0.55Adverse events leading to drug discontinuation214Serious or severe infections01Opportunistic infections00Hypersensitivity reactions47Adverse events leading to death00Analysis of safety population (all participants randomized and treated) as of interim data cut on 15-May-2025.1.TRUTAKNA: cholecystitis, determined by site investigator to be unrelated to treatment; Placebo (n=1 each): gastroenteritis, lower respiratory tract infection, pneumonia, pyelonephritis, IgA nephropathy, renal impairment, acute myocardial infarction, transplant rejection, hyponatremia, osteonecrosis, ovarian epithelial cancer, carotid artery aneurysm, hypertension, acute cholecystitis. 1 placebo serious adverse event was deemed related to study drug.2.Discontinuations in the 2 TRUTAKNA participants were due to eczema and erythema.
Page 14
14© 2026 Vera Therapeutics, Inc. Corporate Presentation •Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027•Pending positive eGFR analysis, plans to submit a supplemental Biologics License Application (sBLA) in Q4 2026, with potential full approval in 2027BRISBANE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it has aligned with the U.S. Food and Drug Administration (FDA) on a revised, earlier ORIGIN 3 eGFR analysis plan to support full approval for atacicept in adults with IgAN. The eGFR results are now expected in the third quarter of 2026. Pending these results, Vera Therapeutics plans to submit an sBLA for full approval in the fourth quarter of 2026.Alignment with the FDA on a revised eGFR analysis plan follows a recent workshop hosted by the National Kidney Foundation which included clinicians, researchers, regulators, and patient advocates. In addition, the alignment with the FDA has been supported by the eGFR results from the ORIGIN Phase 2b trial of atacicept in IgAN. Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Page 15
15© 2026 Vera Therapeutics, Inc. Corporate Presentation Final efficacy analysis: Patient disposition 428 randomized and dosed 15 discontinued treatment8 patient withdrawals4 adverse events22 lost to follow-up1 protocol deviation 45 discontinued treatment22 adverse events310 patient withdrawals10 physician’s decision2 lost to follow-up1 protocol deviation 214 TRUTAKNA214 placebo 750 screened319 failed screening431 randomized 199 (93%)169 (79%) 3 randomized but not dosed1 Treatment ongoing Full analysis set and safety analysis set As of data cut on 10-Jun-2026.1.2 were randomized to atacicept and 1 to placebo, but were not dosed due to randomization error, physician decision, or patient withdrawal.2.The adverse events leading to discontinuation in the atacicept group were splenic abscess, erythema, rash, and injection-site reaction.3.The adverse events leading to discontinuation in the placebo group were chronic kidney disease (n=3), proteinuria (n=2), renal impairment (n=2), acute kidney injury, end-stage renal disease, IgA nephropathy, renal failure, pneumonia, pyelonephritis, upper respiratory tract infection, skin lesion, high-grade B-cell lymphoma, ovarian epithelial cancer, carotid artery aneurysm, Parkinson’s disease, aplastic anemia, parophthalmia, blood creatinine increased, osteonecrosis, and aortic dissection.
Page 16
16© 2026 Vera Therapeutics, Inc. Corporate Presentation Baseline demographics and characteristicsTRUTAKNAn=214Placebon=214Totaln=428Age, years, median (range)41 (18, 74)41 (18, 70)41 (18, 74)Male sex, n (%)122 (57)132 (62)254 (59)Race, n (%)Asian 117 (55)114 (53)231 (54)White 94 (44)95 (44)189 (44)Other 3 (1)5 (2)8 (2)Region, n (%)Americas, Europe, Australia110 (51)108 (50)218 (51)Asia 104 (49)106 (50)210 (49)eGFR, mL/min/1.73m2, mean ± SD65 ± 2763 ± 2764 ± 27UPCR by 24h urine, g/g, mean ± SD1.6 ± 0.91.6 ± 1.01.6 ± 1.0Proteinuria, g/day, mean ± SD2.2 ± 1.12.2 ± 1.22.2 ± 1.1Systolic blood pressure, mmHg, mean ± SD124.1 ± 11.1124.6 ± 11.0124.3 ± 11.0Diastolic blood pressure, mmHg, mean ± SD79.7 ± 8.378.4 ± 8.179.0 ± 8.2Time since biopsy, years, mean ± SD2.6 ± 2.62.3 ± 2.42.4 ± 2.5SGLT2i use, n (%)134 (63)129 (60)263 (61)
Page 17
17© 2026 Vera Therapeutics, Inc. Corporate Presentation TRUTAKNA treatment resulted in a physiologic rate of eGFR loss vs pathologic rate of eGFR loss with placebo 1.Change from baseline in eGFR was analyzed using a mixed model for repeated measures (MMRM). eGFR change from baseline at 52 weeks was the prespecified key secondary endpoint using an analysis of data through 52 weeks. The eGFR change from baseline at 104 weeks was a prespecified exploratory endpoint using an analysis of data through 104 weeks, and the p-value is nominal. 2.Annualized eGFR slope through 104 weeks was a prespecified secondary endpoint and analyzed using a mixed model with random intercept and random slope (MMRIRS). -16-14-12-10-8-6-4-202 Mean change from baseline1Annualized eGFR slope2at 52 weeksat 104 weeksPlacebo-adjusted differenceΔ5.6(3.7, 7.5)p<0.0001Δ11.1(7.7, 14.4)p<0.0001Δ5.0(3.6, 6.5)p<0.0001TRUTAKNA-0.1(-1.4, 1.2)-1.8(-3.9, 0.3)-0.6(-1.6, 0.4) Placebo-5.7(-7.0, -4.4)-12.8(-15.4, -10.3)-5.6(-6.6, -4.6) Mean (95% CI) eGFR change from baseline, mL/min/1.73m2 n=TRUTAKNAPlacebo Week214214209210208208205203 01224365272 104 202193159136 5037 48 197195 60 165155 84 10281 96 7260209209 4
Page 18
18© 2026 Vera Therapeutics, Inc. Corporate Presentation Mean (95% CI) placebo-adjusted eGFR change at 52 weeks, mL/min/1.73m2 Mean (95% CI) placebo-adjusted annualized eGFR slope, mL/min/1.73m2/yrn (%)Overall 428 5.6(3.7, 7.5) 5.0(3.6, 6.5)Age, years<40189 (44) 6.6(3.6, 9.6) 6.6(4.2, 9.0)≥40239 (56) 4.7(2.4, 7.1) 3.7(2.0, 5.4)SexMale254 (59) 4.8(2.4, 7.2) 5.6(3.6, 7.6)Female174 (41) 6.6(3.6, 9.7) 4.0(2.0, 6.0)RegionAmericas, Europe, Australia218 (51) 5.4(3.0, 7.8) 5.0(3.0, 6.9)Asia210 (49) 5.7(2.8, 8.6) 5.0(2.9, 7.2)Race1 White189 (44) 5.2(2.6, 7.8) 4.7(2.5, 6.8)Non-white238 (56) 5.9(3.2, 8.6) 5.3(3.3, 7.3)BL UPCR, g/g<1.5233 (54) 3.5(1.1, 5.9) 3.9(1.9, 5.8)≥1.5195 (46) 7.9(5.0, 10.8)6.3(4.2, 8.3) BL eGFR, mL/min/1.73m2 <45128 (30) 5.2(2.6, 7.9) 4.6(2.5, 6.6)≥45300 (70) 5.9(3.5, 8.4) 5.2(3.3, 7.1)<60227 (53) 5.7(3.4, 7.9) 5.1(3.3, 6.9)≥60201 (47) 5.4(2.3, 8.5) 4.7(2.3, 7.0)SGLT2i use at BLYes 263 (61) 6.0(3.6, 8.3) 5.1(3.4, 6.8)No 165 (39) 4.8(1.6, 8.1) 4.8(2.2, 7.4) Change from baseline in eGFR was analyzed using an MMRM. Annualized eGFR slope was analyzed using an MMRIRS. The confidence intervals for the subgroup analyses were not adjusted for multiplicity and should not be used in place of hypothesis testing; thus, no conclusions regarding individual subgroups can be made.1. Race was not reported for one participant. -12-60612Favors TRUTAKNAFavors Placebo Favors TRUTAKNAFavors Placebo-10-50510 TRUTAKNA eGFR benefit observed across all prespecified subgroups
Page 19
19© 2026 Vera Therapeutics, Inc. Corporate Presentation TRUTAKNA achieved 76% risk reduction in the composite kidney disease progression endpoint A composite kidney disease progression event was defined as ≥1 of the following:•Death•Kidney transplant•Chronic dialysis ≥30 days•eGFR <15 mL/min/1.73m2 sustained for ≥30 days•≥30% eGFR decline sustained for ≥30 days 11 0 38 70 10 20 30 40 Sustained ≥30% eGFR declineDialysis, transplantor death Participants, n 18% 5% Dialysis,1 transplantor death TRUTAKNAPlaceboComposite kidney disease progression through 104 weeksHazard ratioRisk reduction0.24(95% CI 0.12, 0.48)p<0.000176% Hazard ratio, 95% CI, and the likelihood ratio test p-value were calculated based on Cox proportional hazard model.All patients who had composite events first experienced a sustained ≥30% decline in eGFR.1. Does not include one placebo participant who received transient dialysis for acute kidney injury.
Page 20
20© 2026 Vera Therapeutics, Inc. Corporate Presentation Change from baseline in % participants with hematuria (95% CI) -1 00 -8 0 -6 0 -4 0 -2 0 0 0122436524 4860728496104Week TRUTAKNA reduced UPCR, Gd-IgA1, and hematuria through 104 weeksUPCR reduction1 Hematuria resolution3Gd-IgA1 reduction2 52 weeks104 weeks52 weeks104 weeks52 weeks104 weeksPlacebo-5%+9%Placebo+3%+6%Placebo-21%-22%TRUTAKNA-53%-57%TRUTAKNA-66%-63%TRUTAKNA-81%-97%Placebo-adjusted reductionΔ51%p<0.0001Δ60% Placebo-adjusted reductionΔ67%p<0.0001Δ65% p<0.0001 -7 5-6 0-4 5-3 0-1 501530Mean (95% CI) % change from baseline Week01224365272104-7 5 -5 0 -2 5 0 25 Week0122436524 72104 Mean (95% CI) % change from baselineTRUTAKNA Placebo The 52-week estimates were prespecified secondary endpoints using analyses of data through 52 weeks, and 104-week estimates were prespecified exploratory endpoints using analyses of data through 104 weeks. 1. UPCR % reduction was obtained from the geometric mean ratios, where the natural log-transformed ratio to baseline in UPCR (based on 24-hour urine collection) was analyzed using an MMRM model. 2. Gd-IgA1 % reduction was obtained from the geometric mean ratios, where the natural log-transformed ratio to baseline in Gd-IgA1 was analyzed using an MMRM model. 3. The logistic regression model with repeated measurement was used to analyze the proportion of participants achieving hematuria resolution at each postbaseline visit.
Page 21
21© 2026 Vera Therapeutics, Inc. Corporate Presentation TRUTAKNA was well tolerated with a favorable safety profile, and generally comparable to placebo•Most adverse events were mild or moderate in severity and resolved without treatment interruption or discontinuation•Injection site reactions were mild or moderate•Fewer serious adverse events were reported in the TRUTAKNA group compared with placebo •No clinically relevant hypogammaglobulinemia reported•No opportunistic infections reported•No deaths occurred in the TRUTAKNA group•No clinically meaningful effect of anti-drug antibodies on PK, PD, safety or efficacy Participants, n (%)TRUTAKNAn=214Placebon=214Adverse events160 (75)167 (78)Serious adverse events1 15 (7)33 (15)Adverse events leading to drug discontinuation4 (2)22 (10)Adverse events of infections and infestations110 (51)112 (52)Serious or severe infections and infestations6 (3)8 (4)Opportunistic infections00Study drug related adverse events2 75 (35)38 (18)Adverse events associated with injection site reactions354 (25)16 (7)Hypersensitivity reactions21 (10)23 (11)Adverse events leading to death01 (0.5)Analysis of safety population (all participants randomized and treated) as of data cut on 10-Jun-2026.1.In the placebo patients with serious adverse events, 7 had events characterized as kidney and urinary disorders. Additional laboratory-related events included decreased eGFR in 2 patients and increased blood creatinine in 1. There were no kidney/urinary or kidney-related laboratory serious adverse events in the atacicept group.2.Most study drug related adverse events were mild to moderate injection site reactions that did not lead to discontinuation.3.Injection site reactions among TRUTAKNA recipients were largely characterized by injection site erythema, hematoma, and pruritis.
Page 22
22© 2026 Vera Therapeutics, Inc. Corporate Presentation Atacicept in IgA Nephropathy: Phase 3 Trial Final Efficacy Analysispublished inThe New England Journal of Medicine Barratt J, et al. N Engl J Med 2026. doi/full/10.1056/NEJMoa2610103. Scan to visit NEJM.org
Page 23
23© 2026 Vera Therapeutics, Inc. Corporate Presentation Conclusions•ORIGIN 3 demonstrates that TRUTAKNA has the potential for comprehensive disease modification in IgAN•TRUTAKNA treatment resulted in a physiologic rate of eGFR loss compared to a pathologic rate of eGFR loss with placebo•ORIGIN 3 met all prespecified endpoints, including placebo-adjusted eGFR and composite kidney disease progression benefits•TRUTAKNA was well tolerated with a favorable safety profile, and generally comparable to placebo•Study participants are transitioning to open-label atacicept for the remainder of the trial•Submission to US FDA to support potential full approval in 2027; additional regional regulatory submissions expected to followThese results have not been reviewed by FDA and are not part of the approved Prescribing Information.
Page 24
24© 2026 Vera Therapeutics, Inc. Corporate Presentation US IgAN Prevalence: ~0.04% of US Population (360.5M)1 Phase 3populationPhase 2 study ongoing Estimated IgAN epidemiology in 2032 BAFF & APRILinhibition + ~30KModerate Risk(~20% of patients)2 ~160K ~90KHigh Risk (~56% of patients)2 + ~40KLow Risk(~24% of patients)2
Page 25
25© 2026 Vera Therapeutics, Inc. Corporate Presentation •We believe the nephrology market is ripe for disruption due to limited adoption of approved therapies•Large market with unmet need•Growing IgAN population1•Favorable payer mix2 IgAN market and TRUTAKNA have many hallmarks of an attractive commercial opportunity •Potentially differentiating product attributes•Phase 2b eGFR data highly valued with enthusiastic support from therapeutic experts and insights captured at advisory boards3•Experienced commercial team actively promoting in the field•Exciting lifecycle opportunities TRUTAKNAIgAN Market 1. ClearView Healthcare Partners Analysis; 2. Bluepath Solutions research conducted in Q4 2024; 3. Spherix Realtime Dynamix US IgAN independent survey conducted in Q4 2024 and advisory boards conducted by Vera Therapeutics.
Page 26
26© 2026 Vera Therapeutics, Inc. Corporate Presentation ITP gMG SLE Sjögren’s SSc pMN FSGS AAV LN MCD IgAN/IgAVN Potential $10B+ U.S. market opportunity in IgAN and pipeline autoimmune diseases1LCM for BAFF and APRIL inhibitionUS Prevalence1 1. Vera Therapeutics corporate estimates for peak year market opportunity and prevalence based on ClearView Healthcare Partners Analysis 2025.AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; FSGS, focal segmental glomerulosclerosis; gMG, generalized myasthenia gravis; IgAVN, IgA vasculitis nephritis; ITP, immune thrombocytopenia; LCM, lifecycle management; LN, lupus nephritis; MCD, minimal change disease; pMN, primary membranous nephropathy; SLE, systemic lupus erythematosus; SSc, systemic sclerosis. NephrologyNon-Nephrology~500K~700K
Page 27
27© 2026 Vera Therapeutics, Inc. Corporate Presentation TRUTAKNA projected catalysts 1. Subject to U.S. FDA review of full clinical dataset and approval. Vera holds worldwide, exclusive rights to develop and commercialize TRUTAKNA Catalyst202620272028 IgAN US launch Phase 3 final efficacy analysis Projected full approval1 IgANClinical resultsIgAN, pMN, FSGS, MCDClinical results
Page 28
© 2026 Vera Therapeutics, Inc. Corporate Presentation